ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pliva, a Zagreb, Croatia-based drug firm, expects to complete its exit from the proprietary drug business with an agreement to sell an R&D unit to GlaxoSmithKline. GSK will pay an up-front fee of $35 million, subject to the progression of certain early-stage projects into clinical development, and further payments of up to $15 million. Pliva's research arm, Pliva-Istraziva??cki Institut, is focused on the study of macrolides. Separately, Pliva agreed to buy the Spanish generic drug business Uso Racional from the Sandoz subsidiary of Novartis. Pliva says it will pay Sandoz $25.6 million for the generics business, which expects $14 million in sales this year. The Croatian firm announced plans to narrow its focus to its generics business in May 2005. In November, it sold its U.S.-branded subsidiary Odyssey Pharmaceuticals to Dava Pharmaceuticals.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X